Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Two Decade Single Institution Experience Highlights Rare Survivors with Relapsed or Refractory Burkitt Lymphoma

Blood (2024) 144 (Supplement 1): 6520.

https://doi.org/10.1182/blood-2024-210617

Published: 2024

Journal Articles

A Niche Driven Mechanism Determines Response to ATRA and a Mutation-Independent Therapeutic Approach for MDS and AML

Ioanna Mosialou, Abdullah Mahmood Ali, Alvaro Cuesta-Dominguez, Rossella Labella, Voula Vgenopoulou, Brygida Bisikirska, Marta Galan-Diez, Anqi Wang, Jan Philipp Bewersdorf, Cui Liang, Mael Heiblig, Joseph G Jurcic, Ellin Berman, Raul Rabadan, Steven M. Kornblau, Guillermo Garcia-Manero, Azra Raza, Stavroula Kousteni

Blood (2024) 144 (Supplement 1): 5788.

https://doi.org/10.1182/blood-2024-212307

Published: 2024

Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Blood (2024) 144 (Supplement 1): 221.

https://doi.org/10.1182/blood-2024-201595

Published: 2024

Journal Articles

Adult AML Patients with NUP98 Fusions Are Frequently Therapy-Related, and Are Associated with Monocytic Differentiation, Recurring Mutations in NRAS , DNMT3A and WT1 and Poor Outcome

Jinjuan Yao, Umut Aypar, Shenon Sethi, Leora Boussi, Dory Londono, Purvil Sukhadia, Ellin Berman, Eytan M. Stein, Ahmet Dogan, Wenbin Xiao, Yanming Zhang

Blood (2024) 144 (Supplement 1): 1556.

https://doi.org/10.1182/blood-2024-203634

Published: 2024

Journal Articles

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav Gupta, Prabhakar Borge, Ellin Berman, Mark Blaine Geyer, Aaron D. Goldberg, Tamanna Haque, Raajit K. Rampal, Jae H. Park, Lindsey E. Roeker, Martin S. Tallman, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 1519.

https://doi.org/10.1182/blood-2023-182012

Published: 2023

Journal Articles

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Blood (2022) 140 (Supplement 1): 2137–2139.

https://doi.org/10.1182/blood-2022-157193

Published: 2022

Journal Articles

How I treat chronic-phase chronic myelogenous leukemia

Ellin Berman

Blood (2022) 139 (21): 3138–3147.

https://doi.org/10.1182/blood.2021011722

Published: 2022

Journal Articles

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori Leslie, John M. Pagel, Krish Patel, Anders Osterborg, Daniel Wojenski, Manali Kamdar, Scott F. Huntington, Matthew S. Davids, Jennifer R. Brown, Darko Antic, Ryan Jacobs, Inhye E. Ahn, Jeffrey Pu, Krista M. Isaac, Paul M. Barr, Chaitra S. Ujjani, Mark B. Geyer, Ellin Berman, Andrew D. Zelenetz, Nikita Malakhov, Richard R. Furman, Michael Koropsak, Neil Bailey, Lotta Hanson, Guilherme F. Perini, Shuo Ma, Christine E. Ryan, Adrian Wiestner, Craig A. Portell, Mazyar Shadman, Elise A. Chong, Danielle M. Brander, Suchitra Sundaram, Amanda N. Seddon, Erlene Seymour, Meera Patel, Nicolas Martinez-Calle, Talha Munir, Renata Walewska, Angus Broom, Harriet Walter, Dima El-Sharkawi, Helen Parry, Matthew R. Wilson, Piers E. M. Patten, José-Ángel Hernández-Rivas, Fatima Miras, Noemi Fernández Escalada, Paola Ghione, Chadi Nabhan, Sonia Lebowitz, Erica Bhavsar, Javier López-Jiménez, Daniel Naya, Jose Antonio Garcia-Marco, Sigrid S. Skånland, Raul Cordoba, Toby A. Eyre

Blood (2020) 136 (10): 1134–1143.

https://doi.org/10.1182/blood.2020006965

Published: 2020

Includes: Supplemental data

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Aaron D Goldberg, MD, Troy Z. Horvat, PharmD, BCOP, Meier Hsu, MS, Sean M. Devlin, PhD, Bernadette M. Cuello, BSN, MSN, NP, RN, Ryan J. Daley, PharmD, BCOP, Amber C. King, PharmD, BCOP, Larry W Buie, PharmD, BCOP, FASHP, Jacob L Glass, MDPhD, Michael J. Mauro, MD, Eytan M. Stein, MD, Ellin Berman, MD, Virginia M. Klimek, MD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 1353.

https://doi.org/10.1182/blood.V130.Suppl_1.1353.1353

Published: 2017

Journal Articles

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Blood (2017) 130 (Supplement 1): 891.

https://doi.org/10.1182/blood.V130.Suppl_1.891.891

Published: 2017

Journal Articles

Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1

Aaron D Goldberg, MD, Noushin Farnoud, PhD, Cody Goldberger, Minal Patel, BA, Christopher Famulare, MS, Juan Medina, Raajit K. Rampal, MD PhD, Ross L. Levine, MD, Ellin Berman, MD, Yanming Zhang, MD, Filiz Sen, MD, Elli Papaemmanuil, PhD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 2663.

https://doi.org/10.1182/blood.V130.Suppl_1.2663.2663

Published: 2017

Journal Articles

Activation Levels of b-Catenin Signaling in Osteoblasts Define a Threshold for the Development of Myeloid Neoplasia of Variable Severity

Ioanna Mosialou, PhD, Alvaro Cuesta-Dominiguez, PhD, Govind Bhagat, MD, Ellin Berman, MD, Azra Raza, MD, Stavroula Kousteni, PhD

Blood (2017) 130 (Supplement 1): 2946.

https://doi.org/10.1182/blood.V130.Suppl_1.2946.2946

Published: 2017

Journal Articles

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Blood (2016) 128 (22): 5109.

https://doi.org/10.1182/blood.V128.22.5109.5109

Published: 2016

Journal Articles

Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia

Masahiro Marshall Nakagawa, Aruna Kode, Sanil J Manavalan, Govind Bhagat, MD, Julie Teruya-Feldstein, MD, Azra Raza, MD, Ellin Berman, MD, Stavroula Kousteni

Blood (2015) 126 (23): 2551.

https://doi.org/10.1182/blood.V126.23.2551.2551

Published: 2015

Journal Articles

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Gabriella Hobbs, MD, Rivka Litvin, Jihae Ahn, Anna Sophia Mckenney, Michael J. Mauro, MD, Martin S Tallman, MD, Ellin Berman, MD, Mark Lawrence Heaney, MD PhD, Ross L. Levine, MD, Raajit K. Rampal, MD, PhD

Blood (2015) 126 (23): 4075.

https://doi.org/10.1182/blood.V126.23.4075.4075

Published: 2015

Journal Articles

Foxo1 Expressed in Osteoblasts Promotes the Leukemogenic Properties of β-Catenin By Activating Notch Signaling

Aruna Kode, Ioanna Mosialou, Sanil J Manavalan, Julie Teruya Feldstein, Govind Bhagat, MD, Ellin Berman, MD, Stavroula Kousteni

Blood (2014) 124 (21): 2356.

https://doi.org/10.1182/blood.V124.21.2356.2356

Published: 2014

Journal Articles

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts

Blood (2014) 124 (18): 2834–2846.

https://doi.org/10.1182/blood-2013-07-517219

Published: 2014

Includes: Supplemental data

Journal Articles

High-Dose Cytarabine Monotherapy Versus Intermediate Or High-Dose Cytarabine In Combination With Other Agents As Second-Line Salvage Therapy In Patients With Acute Myeloid Leukemia Who Did Not Respond To Initial Induction Therapy

Thu Oanh T Dang, PharmD, BCOP, Patrick Hilden, MS, Sean M. Devlin, PhD, Raajit K. Rampal, M.D., Ph.D., Ross L. Levine, MD, Ellin Berman, MD, Virginia M. Klimek, M.D., Nelly G. Adel, PharmD, BCOP, BCPS, Martin S. Tallman, MD

Blood (2013) 122 (21): 2695.

https://doi.org/10.1182/blood.V122.21.2695.2695

Published: 2013

NARROW

Two Decade Single Institution Experience Highlights Rare Survivors with Relapsed or Refractory Burkitt Lymphoma

A Niche Driven Mechanism Determines Response to ATRA and a Mutation-Independent Therapeutic Approach for MDS and AML

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Adult AML Patients with NUP98 Fusions Are Frequently Therapy-Related, and Are Associated with Monocytic Differentiation, Recurring Mutations in NRAS , DNMT3A and WT1 and Poor Outcome

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

How I treat chronic-phase chronic myelogenous leukemia

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies

Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles

Molecular Profiling in Extramedullary Acute Myeloid Leukemia Reveals Distinct Subgroups Defined By Mutations in KIT and RUNX1

Activation Levels of b-Catenin Signaling in Osteoblasts Define a Threshold for the Development of Myeloid Neoplasia of Variable Severity

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Targeting the Osteoblast in Myelodysplasia and Acute Myeloid Leukemia

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Foxo1 Expressed in Osteoblasts Promotes the Leukemogenic Properties of β-Catenin By Activating Notch Signaling

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts

High-Dose Cytarabine Monotherapy Versus Intermediate Or High-Dose Cytarabine In Combination With Other Agents As Second-Line Salvage Therapy In Patients With Acute Myeloid Leukemia Who Did Not Respond To Initial Induction Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only